Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics

References

• World Health OrganizationHIV/AIDS fact sheet2013 Available from: http://www.who.int/mediacentre/factsheets/fs360/en/index.htmlAccessed March 15, 2013
   Google Scholar
• World Health OrganizationMother-to-child transmission of HIV Available from: http://www.who.int/hiv/topics/mtct/en/index.htmlAccessed March 18, 2013
   Google Scholar
• World Health OrganizationTreatment of children living with HIV Available from: http://www.who.int/hiv/topics/paediatric/en/index.htmlAccessed March 15, 2013
   Google Scholar
• Food and Drug AdministrationIsentress (raltegravir) tablets Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022145s004lbl.pdfAccessed March 15, 2013
   Google Scholar
• MarkowitzMMorales-RamirezJONguyenBYAntiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individualsJ Acquir Immune Defic Syndr200643550951517133211
   PubMed Web of Science ®Google Scholar
• MillerMWitmerMStillmockKBiochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitorPresented at: Oral abstract session of AIDS 2006 – XVI International AIDS ConferenceAugust 13–18, 2006Toronto, Canada Abstract THAA0302
   Google Scholar
• SteigbigelRTCooperDAKumarPNRaltegravir with optimized background therapy for resistant HIV-1 infectionN Engl J Med2008359433935418650512
   PubMed Web of Science ®Google Scholar
• EronJJCooperDASteigbigelRTefficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsLancet Infect Dis201313758759623664333
   PubMed Web of Science ®Google Scholar
• AIDSinfoGuidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents2013 Available from: http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0Accessed May 23, 2013
   Google Scholar
• MarkowitzMNguyenBYGotuzzoERapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-naive Patients with HIV-1 Infection: Results of a 48-week Controlled StudyJ Acquir Immune Defic Syndr200746212513317721395
   PubMed Web of Science ®Google Scholar
• MarkowitzMNguyenBYGotuzzoESustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-naive Patients with HIV-1 InfectionJ Acquir Immune Defic Syndr200952335035619648823
   PubMed Web of Science ®Google Scholar
• VispoEBarreiroPMaidaISimplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trialHIV Clin Trials201011419720420974575
   PubMed Web of Science ®Google Scholar
• EronJJJrRockstrohJKReynesJRaltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trialLancet Infect Dis2011111290791521933752
   PubMed Web of Science ®Google Scholar
• SandkovskyUSwindellsSRobbinsBLNelsonSRAcostaEPFletcherCVMeasurement of plasma and intracellular concentrations of raltegravir in patients with HIV infectionAIDS201226172257225922948265
   PubMed Web of Science ®Google Scholar
• IwamotoMWenningLANguyenBYEffects of omeprazole on plasma levels of raltegravirClin Infect Dis200948448949219143531
   PubMed Web of Science ®Google Scholar
• KassahunKMcIntoshICuiDMetabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzymeDrug Metab Dispos20073591657166317591678
   PubMed Web of Science ®Google Scholar
• WenningLAHanleyWDBrainardDMEffect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravirAntimicrob Agents Chemother20095372852285619433563
   PubMed Web of Science ®Google Scholar
• IwamotoMWenningLAMistryGCAtazanavir modestly increases plasma levels of raltegravir in healthy subjectsClin Infect Dis200847113714018513146
   PubMed Web of Science ®Google Scholar
• NeelyMDecosterdLFayetAPharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteersAntimicrob Agents Chemother201054114619462520823282
   PubMed Web of Science ®Google Scholar
• AndersonMSKakudaTNHanleyWMinimal pharmacokinetic interaction between the human immunodeficiency virus non-nucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjectsAntimicrob Agents Chemother200852124228423218838586
   PubMed Web of Science ®Google Scholar
• MénardASolasCMokthariSEtravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four casesAIDS200923786987119363331
   PubMed Web of Science ®Google Scholar
• IwamotoMWenningLAPetryASMinimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of RaltegravirAntimicrob Agents Chemother200852124338434318838589
   PubMed Web of Science ®Google Scholar
• ShearerWTQuinnTCLaRussaPViral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study GroupN Engl J Med199733619133713429134873
   PubMed Web of Science ®Google Scholar
• PalumboPEKwokSWatersSViral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infantsJ Pediatr199512645925957699539
   PubMed Web of Science ®Google Scholar
• BrizVLeón-LealJAPalladinoCPotent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescentsPediatr Infect Dis J201231327327722330165
   PubMed Web of Science ®Google Scholar
• AveryGBRandolphJGWeaverTGastric acidity in the first day of lifePediatrics1966376100510075949019
   PubMed Web of Science ®Google Scholar
• Strolin BenedettiMBaltesELDrug metabolism and disposition in childrenFundam Clin Pharmacol200317328129912803568
   PubMed Web of Science ®Google Scholar
• KingJAcostaEPediatric clinical pharmacology and its implications for antiretroviral drug developmentCurr Opin HIV AIDS20083327227619372978
   PubMed Web of Science ®Google Scholar
• StrassburgCPStrassburgAKneipSDevelopmental aspects of human hepatic drug glucuronidation in young children and adultsGut200250225926511788570
   PubMed Web of Science ®Google Scholar
• NachmanSAcostaEZhengNIMPAACT P1066: raltegravir (RAL) safety and efficacy in HIV infected (+) youth two to 18 years of age through week 48Presented at: 19th International AIDS ConferenceJuly 22–27, 2012Washington, DC Abstract TUAB0205
   Google Scholar
• SpectorSAcostaEPZhengNRaltegravir oral granules formulation in children 6 months to <2 years of age: interim results from IMPAACT P1066Programs and abstracts of the 19th Conference on Retroviruses and Opportunistic InfectionsMarch 5–8, 2012Seattle, WA Abstract 987
   Google Scholar
• ThuretIChaixM-LTamaletCRaltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virusAIDS200923172364236619823069
   PubMed Web of Science ®Google Scholar
• BestBMCapparelliEStekARaltegravir pharmacokinetics during pregnancyPrograms and abstracts of the 50th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 12–15, 2010Boston, MA
   Google Scholar
• ColbersAMoltoJIvanovicJA comparison of the pharmacokinetics of raltegravir during pregnancy and post-partumPrograms and abstracts of the 12th International Workshop on Clinical Pharmacology of HIV TherapyApril 13–15, 2011Miami, FL
   Google Scholar
• JaworskyDThompsonCYudinMHUse of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two casesAntivir Ther201015467768020587860
   PubMed Web of Science ®Google Scholar
• PinnettiCBaroncelliSVillaniPRapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancyJ Antimicrob Chemother20106592050205220630894
   PubMed Web of Science ®Google Scholar
• WestlingKPetterssonKKaldmaANavérLRapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancyAIDS Patient Care STDS2012261271471723101466
   PubMed Web of Science ®Google Scholar
• ClarkeDAcostaEPRizkMLRaltegravir pharmacokinetics and safety in neonates (IMPAACT P1097)Programs and abstracts of the 20th Conference on Retroviruses and Opportunistic InfectionsMarch 3–6, 2013Atlanta, GA
   Google Scholar
• JohnsonVACalvezVGunthardHFUpdate of the drug resistance mutations in HIV-1: Mar 2013Top Antivir Med201321161423596273
   PubMedGoogle Scholar
• SichtigNSierraSKaiserREvolution of raltegravir resistance during therapyJ Antimicrob Chemother2009641253219447792
   PubMed Web of Science ®Google Scholar
• GatellJMKatlamaCGrinsztejnBLong-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II studyJ Acquir Immune Defic Syndr201053445646320306554
   PubMed Web of Science ®Google Scholar
• GarridoCVillacianJZahoneroNBroad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimensAntimicrob Agents Chemother20125662873287822450969
   PubMed Web of Science ®Google Scholar
• UnderwoodMRJohnsBASatoAMartinJNDeeksSGFujiwaraTThe activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adultsJ Acquir Immune Defic Syndr201261329730122878423
   PubMed Web of Science ®Google Scholar
• KobayashiMYoshinagaTSekiTIn vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitorAntimicrob Agents Chemother201155281382121115794
   PubMed Web of Science ®Google Scholar
• PersaudDGayHZiemniakCFFunctional HIV Cure after Very Early ART of an Infected InfantPrograms and abstracts of the 20th Conference on Retroviruses and Opportunistic InfectionsMarch 3–6, 2013Atlanta, GA Abstract 48LB
   Google Scholar